animal model is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Deep learning uses several layers of neurons between the network's inputs and outputs. The multiple layers can progressively extract higher-level features from the raw input. For example, in image processing, lower layers may identify edges, while higher layers may identify the concepts relevant to a human such as digits, letters, or faces. Deep learning has been used to improve the performance of programs in subfields of artificial intelligence including computer vision, speech recognition, natural language processing, image classification and others. Deep neural networks and backpropagation had been in development since 1950. Starting in 2012, the speed of deep learning was increased one hundred-fold by switching to GPUs, and there were enormous amounts of data available on the internet (called at the time "big data") as well as curated datasets used for benchmark testing, such as ImageNet. Usage of deep learning increased in 2012–2015 due to these improvements. In 2025, Geoffrey Hinton said that, until the 2010s, "We couldn't do anything very impressive because we didn’t have enough data and we didn't have enough computation."
Many lower-resource languages (ex. Wolof, Xhosa) were translated across more languages than higher-resource languages (ex. English, French). In September 2024, Robyn Speer, the author of wordfreq, an open source database that calculated word frequencies based on text from the Internet, announced that she had stopped updating the data for several reasons: high costs for obtaining data from Reddit and Twitter, excessive focus on generative AI compared to other methods in the natural language processing community, and that "generative AI has polluted the data". The adoption of generative AI tools led to an explosion of AI-generated content across multiple domains. A study from University College London estimated that in 2023, more than 60,000 scholarly articles—over 1% of all publications—were likely written with LLM assistance. According to Stanford University's Institute for Human-Centered AI, approximately 17.5% of newly published computer science papers and 16.9% of peer review text now incorporate content generated by LLMs. If AI-generated content is included in new data crawls from the Internet for additional training of AI models, defects in the resulting models may occur. Training an AI model exclusively on the output of another AI model produces a lower-quality model. Repeating this process, where each new model is trained on the previous model's output, leads to progressive degradation and eventually results in a "model collapse" after multiple iterations.
The plantar fascia is a thick fibrous band of connective tissue that originates from the medial tubercle and anterior aspect of the heel bone. From there, the fascia extends along the sole before inserting at the base of the toes and supports the arch. Plantar fasciitis is a non-inflammatory condition. Studies reported microscopic anatomical changes indicating that plantar fasciitis is due to a non-inflammatory structural breakdown of the plantar fascia, leading to calls rename the condition. Repetitive microtrauma (small tears) appears to cause a structural breakdown of the plantar fascia. Microscopic examination shows myxomatous degeneration, connective tissue calcium deposits, and disorganized collagen fibers. Disruptions in normal mechanical movement during standing and walking (known as the Windlass mechanism) place excess strain on the calcaneal tuberosity and may contribute to symptom development. Other studies have suggested that plantar fasciitis may be a tendon injury involving the flexor digitorum brevis muscle located immediately above the plantar fascia.
Sources: en.wikipedia.org
=== Mechanism === Arsenite inhibits not only the formation of acetyl-CoA but also the enzyme succinic dehydrogenase. Arsenate can replace phosphate in many reactions. It can form Glc-6-arsenate in vitro; therefore, it has been argued that hexokinase could be inhibited. (Eventually this may be a mechanism leading to muscle weakness in chronic arsenic poisoning.) In the glyceraldehyde 3-phosphate dehydrogenase reaction arsenate attacks the enzyme-bound thioester. The formed 1-arseno-3-phosphoglycerate is unstable and hydrolyzes spontaneously. Thus, ATP formation in glycolysis is inhibited while bypassing the phosphoglycerate kinase reaction. (Moreover, the formation of 2,3-bisphosphoglycerate in erythrocytes might be affected, followed by a higher oxygen affinity of hemoglobin and subsequently enhanced cyanosis.) As shown by Gresser (1981), submitochondrial particles synthesize adenosine-5'-diphosphate-arsenate from ADP and arsenate in presence of succinate. Thus, by a variety of mechanisms, arsenate leads to an impairment of cell respiration and subsequently diminished ATP formation. This is consistent with observed ATP depletion of exposed cells and histopathological findings of mitochondrial and cell swelling, glycogen depletion in liver cells and fatty change in liver, heart and kidney. Experiments demonstrated enhanced arterial thrombosis in a rat animal model, elevations of serotonin levels, thromboxane A[2], and adhesion proteins in platelets, while human platelets showed similar responses.
==== Step 3: Termination ==== The last stage of translation occurs when a stop codon enters the A site. Then, the following steps occur: 1. The recognition of codons by release factors, which causes the hydrolysis of the polypeptide chain from the tRNA located in the P site 2. The release of the polypeptide chain 3. The dissociation and "recycling" of the ribosome for future translation processes A summary table of the key players in translation is found below:
An old qualitative test for the presence of the alkene functional group is that alkenes turn brown aqueous bromine solutions colourless, forming a bromohydrin with some of the dibromoalkane also produced. The reaction passes through a short-lived strongly electrophilic bromonium intermediate. This is an example of a halogen addition reaction.
Sources: en.wikipedia.org
== Early life and education == White was born in Wewoka, Oklahoma, in May 1940. White earned an amateur radio license at age 13 and a commercial Second-Class Radiotelephone License at the age of 17. He enrolled at the University of Colorado, eventually majoring in physics. After his graduation in 1963, he enrolled at the University of Washington, and received a master's degree in physics in 1965 under H.G. Dehmelt (Department of Physics) on the radio frequency spectrum of the H2+ ion. In 1969, he earned his doctoral degree in physiology and biophysics for his work planar lipid bilayers in the lab of J. Walter Woodbury. Prior to completing his postdoctoral studies at the University of Virginia in 1972, White served two years in the U.S. Army to the rank of captain.
At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for US$2,000,000 and future milestone and royalty payments. Repligen has made several acquisitions through the early 2020s, including BioFlex Solutions and Tantti Laboratory Inc. among others. As of 2024, the company's President and Chief Executive Officer is Olivier Loeillot. As of 2025 it employs approximately 2,000 employees across several sites in the United States, Europe, and Asia.
Spirulina is the dried biomass of cyanobacteria (blue-green algae) that can be consumed by humans and animals. The three species are Arthrospira platensis, A. fusiformis, and A. maxima. Recent research has further moved all these species to Limnospira. L. fusiformis is also found to be insufficiently different from L. maxima to be its own species. The genus Arthrospira was formerly classified in the genus Spirulina, hence the name. Cultivated worldwide, spirulina is used as a dietary supplement or whole food. It is also used as a feed supplement in the aquaculture, aquarium, and poultry industries.
The Affordable Insulin Now Act is a bill in the United States Congress intended to cap out-of-pocket insulin prices under private health insurance and Medicare at no more than $35 per month. The bill was first introduced on February 25, 2022, by Representative Angie Craig (D-MN). On March 31, 2022, the bill passed the House of Representatives, 232–193. A version of the bill contained in the Inflation Reduction Act (IRA) for private health insurance was blocked by Senate Republicans on August 8, 2022. However, the inflation reduction legislation did cap out-of-pocket insulin cost at $35 per monthly prescription for the following:
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.